Save over 60% on brand Lupkynis from Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for European Lupkynis
Millmount Healthcare Limited
Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YD60,
Ireland.
Information about Lupkynis (Voclosporin)
Lupkynis is a prescription medication used primarily to treat systemic lupus erythematosus (SLE), particularly in patients with active lupus nephritis. Voclosporin is an oral calcineurin inhibitor that helps modulate the immune system to reduce inflammation and prevent organ damage.
Product Highlights
- Inhibits T-cell activation and reduces cytokine production, helping to control the immune response.
- Used as part of a comprehensive treatment regimen for patients with active lupus nephritis.
Key Ingredient
Key Benefits
- Helps reduce proteinuria and improves kidney function in patients with lupus nephritis.
- Aims to decrease overall disease activity in systemic lupus erythematosus.
- Taken orally, which can improve patient adherence.
Direction of Use
- Typically, the recommended starting dose is 23.7 mg twice daily, but the healthcare provider may adjust based on the patient’s response and tolerability.
- Should be taken consistently with or without food, but should be taken the same way each time.
Safety Concerns
- May include increased risk of infections, hypertension, and kidney problems.
- Regular monitoring of kidney function and blood pressure is recommended during treatment.
Avoid Lupkynis (Voclosporin) If
- History of hypersensitivity to voclosporin or any component of the formulation.
- Patients with severe renal impairment (eGFR < 30 mL/min).
- Certain medications that may interact adversely, such as strong CYP3A inhibitors, should be avoided.
